<DOC>
	<DOCNO>NCT00016861</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness irinotecan treat child refractory progressive solid tumor .</brief_summary>
	<brief_title>Irinotecan Treating Children With Refractory Progressive Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxicity irinotecan child refractory progressive solid tumor . - Determine pharmacokinetics drug metabolite ( SN-38 , SN-38G , APC ) administer without concurrent anticonvulsant patient population . - Determine benefit drug offer patient population . OUTLINE : This dose-escalation , multicenter study . Patients accrue stratum 1 initially stratum 2 stratum 1 close due dose-limiting toxicity myelosuppression diarrhea . Patients anticonvulsant accrue stratum 3 must meet eligibility criterion stratum open ( stratum 1 stratum 2 ) . ( Stratum 1 close 2002-09-15 ) . Patients receive irinotecan IV 90 minute weekly 4 week . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) without anticonvulsant determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 6 month 4 year annually thereafter . PROJECTED ACCRUAL : Approximately 20-25 patient accrue study .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor refractory standard therapy know effective therapy exist Brain tumor eligible Histologic verification waive brain stem glioma Evaluable disease No bone marrow involvement PATIENT CHARACTERISTICS : Age : 1 21 Performance status : Karnofsky 50100 % ( age 10 ) Lansky 50100 % ( age 10 ) Life expectancy : At least 8 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8 g/dL Hepatic : Bilirubin le 1.5 mg/dL SGPT le 5 time normal Renal : Creatinine normal OR Glomerular filtration rate least 70 mL/min Other : No uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior autologous bone marrow transplantation ( BMT ) ( include stem cell rescue highdose chemotherapy ) At least 1 week since prior growth factor No prior BMT total body irradiation ( stratum I ) No prior BMT without total body irradiation ( stratum 2 ) No prior allogeneic BMT ( stratum ) No concurrent sargramostim ( GMCSF ) No concurrent prophylactic growth factor support first course therapy Chemotherapy : At least 3 week since prior myelosuppressive chemotherapy ( 6 week nitrosoureas ) No prior irinotecan No 2 prior multiagent chemotherapy regimen ( stratum 2 ) No concurrent chemotherapy Endocrine therapy : Concurrent dexamethasone allow stable decrease dose least 2 week prior study Radiotherapy : At least 6 month since prior craniospinal radiotherapy radiotherapy 50 % pelvis At least 6 week since prior substantial bone marrow radiotherapy No prior central axis radiotherapy , pelvic radiotherapy , and/or total abdominal radiotherapy ( stratum 2 ) Surgery : Not specify Other : Recovered prior therapy No concurrent investigational agent Concurrent enzymeinducing anticonvulsant ( e.g. , phenytoin , phenobarbital , carbamazepine ) allow stable dose least 2 week prior study ( stratum 3 ) Concurrent valproic acid allow combined another enzyme induce anticonvulsant drug ( stratum 3 )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>